|
 |
|
|||||||
|
|||||||||
© 2005 The American Thoracic Society
Overview of Virus-induced Airway Disease
Department of Respiratory Medicine, National Heart and Lung Institute and Wright Fleming Institute of Infection and Immunity, Imperial College London, London, United Kingdom
Correspondence and requests for reprints should be addressed to Sebastian L. Johnston, M.D., Ph.D., Professor of Respiratory Medicine, Department of Respiratory Medicine, National Heart & Lung Institute and Wright Fleming Institute of Infection & Immunity, Imperial College London, Norfolk Place, London W2 1PG, UK. E-mail: s.johnston{at}imperial.ac.uk
Acute exacerbations of asthma and chronic obstructive pulmonary disease (COPD) are the major cause of morbidity, mortality, and health costs of both diseases. Currently available treatments are poorly effective in both acute treatment of and prevention of acute exacerbations. New treatments for intervention and prophylaxis are therefore required; to facilitate their development, we must understand the causes and mechanisms of exacerbations. Respiratory viral infections (2/3 rhinoviruses) precipitate 80% or more of asthma exacerbations in children, and the majority of exacerbations of asthma and COPD in adults, but mechanisms of virus-induced lower airway inflammation and of host resistance against respiratory viruses are poorly understood. Development of in vitro experimental models of virus infection has identified interferon-ß and nitric oxide as possible therapeutic targets to augment antiviral immunity, and nuclear factor-
B as a target for development of anti-inflammatory therapies. In vivo models could also serve to identify and validate targets and as an experimental system to test candidate molecules as they emerge into clinical studies. Studies in asthma have paved the way for development of an asthma model; a similar experimental model in COPD would accelerate development of new therapies for these common diseases with enormous burdens of illness.
Key Words: acute exacerbations • asthma • chronic obstructive pulmonary disease • virus infections
This article has been cited by other articles:
|
|
 |
|
  B. Jakiela, R. Brockman-Schneider, S. Amineva, W.-M. Lee, and J. E. Gern Basal Cells of Differentiated Bronchial Epithelium Are More Susceptible to Rhinovirus Infection Am. J. Respir. Cell Mol. Biol., May 1, 2008; 38(5): 517 - 523. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. Liu, R. C. Gualano, M. L. Hibbs, G. P. Anderson, and S. Bozinovski Epidermal Growth Factor Receptor Signaling to Erk1/2 and STATs Control the Intensity of the Epithelial Inflammatory Responses to Rhinovirus Infection J. Biol. Chem., April 11, 2008; 283(15): 9977 - 9985. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 N. W. Johnston The Similarities and Differences of Epidemic Cycles of Chronic Obstructive Pulmonary Disease and Asthma Exacerbations Proceedings of the ATS, December 1, 2007; 4(8): 591 - 596. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Kato, S. Favoreto Jr., P. C. Avila, and R. P. Schleimer TLR3- and Th2 Cytokine-Dependent Production of Thymic Stromal Lymphopoietin in Human Airway Epithelial Cells J. Immunol., July 15, 2007; 179(2): 1080 - 1087. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Kato, A. Q. Truong-Tran, A. L. Scott, K. Matsumoto, and R. P. Schleimer Airway Epithelial Cells Produce B Cell-Activating Factor of TNF Family by an IFN-beta-Dependent Mechanism J. Immunol., November 15, 2006; 177(10): 7164 - 7172. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 N W Johnston and M R Sears Asthma exacerbations {middle dot} 1: Epidemiology. Thorax, August 1, 2006; 61(8): 722 - 728. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. M. Fabbri, F. Luppi, B. Beghe, and K. F. Rabe Update in chronic obstructive pulmonary disease 2005. Am. J. Respir. Crit. Care Med., May 15, 2006; 173(10): 1056 - 1065. [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |